Evidence map›Paper›PMID 30062507›Full record

ReviewClinical & experimental metastasis2018

The role of radiation therapy in the treatment of metastatic cancer.

Baldassarre Stea, Tijana Skrepnik, Charles C Hsu, Roy Abendroth

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical & experimental metastasis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Critically ill patients with cancer: A clinical perspective.World journal of clinical oncology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Baldassarre SteaDepartment of Radiation Oncology, University of Arizona, 1501 N Campbell Ave, Tucson, AZ, 85724, USA. bstea@email.arizona.edu.ORCID 0000-0003-1895-2248
Tijana SkrepnikDepartment of Radiation Oncology, University of Arizona, 1501 N Campbell Ave, Tucson, AZ, 85724, USA.
Charles C HsuDepartment of Radiation Oncology, University of Arizona, 1501 N Campbell Ave, Tucson, AZ, 85724, USA.
Roy AbendrothDepartment of Radiation Oncology, Sutter Health California Pacific Medical Center, San Francisco, CA, USA.
University of Arizona · USSutter Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiation therapy continues to play an important role in the management of cancer. In this review, we discuss the use of radiation therapy to target and control micrometastatic disease (adjuvant use of radiation), or using stereotactic radiation therapy to address small volumes of gross disease, such as oligometastases, and finally the use of radiation therapy in the era of immunotherapy. Radiation therapy is commonly used to treat nodal basins suspected of harboring microscopic disease. More recently, computer and technical innovations have allowed radiation oncologists to treat small volumes of gross disease within the brain and also in the body with great success, adding to the cancer armamentarium. This modality of cancer treatment that began shortly after the discovery of X-rays by William Roentgen continues to evolve and finds new clinical applications which minimize toxicity while increasing effectiveness. The newly discovered interactions of high dose/fraction radiation (stereotactic radiosurgery) with immune check point inhibitors in melanoma is the latest example of how synergism can be achieved between two different modalities thus increasing the therapeutic ratio to control metastatic cancer.

Indexed as

RadiosurgeryBrain NeoplasmsCombined Modality TherapyHumansMelanomaNeoplasm MicrometastasisAdjuvant radiationImmune checkpoint inhibitorsOligometastatic diseaseStereotactic radiosurgerySynergism of stereotactic radiosurgery

Identifiers

PMID30062507
OpenAlexW2886322321

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.